The Manufacturers Life Insurance Company Acquires New Holdings in Compass Therapeutics, Inc. (NASDAQ:CMPX)

The Manufacturers Life Insurance Company bought a new position in shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm bought 42,671 shares of the company’s stock, valued at approximately $79,000.

Other hedge funds have also recently bought and sold shares of the company. SG Americas Securities LLC increased its position in shares of Compass Therapeutics by 16.6% during the third quarter. SG Americas Securities LLC now owns 38,665 shares of the company’s stock worth $71,000 after acquiring an additional 5,515 shares in the last quarter. Rhumbline Advisers lifted its position in Compass Therapeutics by 10.3% in the 2nd quarter. Rhumbline Advisers now owns 131,789 shares of the company’s stock valued at $132,000 after acquiring an additional 12,315 shares in the last quarter. Rovin Capital UT ADV acquired a new position in Compass Therapeutics in the 3rd quarter worth $25,000. Intech Investment Management LLC bought a new position in Compass Therapeutics during the 3rd quarter worth about $30,000. Finally, Bank of New York Mellon Corp raised its stake in shares of Compass Therapeutics by 12.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 283,938 shares of the company’s stock valued at $284,000 after purchasing an additional 31,433 shares during the period. 68.43% of the stock is currently owned by institutional investors and hedge funds.

Compass Therapeutics Stock Performance

Shares of NASDAQ CMPX opened at $1.53 on Wednesday. The stock has a 50 day moving average price of $1.67 and a 200 day moving average price of $1.41. The stock has a market capitalization of $210.51 million, a PE ratio of -4.14 and a beta of 0.89. Compass Therapeutics, Inc. has a 52 week low of $0.77 and a 52 week high of $2.34.

Compass Therapeutics (NASDAQ:CMPX) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.03. As a group, research analysts forecast that Compass Therapeutics, Inc. will post -0.35 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the company. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price objective on shares of Compass Therapeutics in a research report on Monday, November 11th. Leerink Partnrs downgraded Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 15th. LADENBURG THALM/SH SH raised shares of Compass Therapeutics from a “neutral” rating to a “buy” rating and set a $5.00 price target for the company in a research note on Monday, September 16th. Finally, Leerink Partners lowered shares of Compass Therapeutics from an “outperform” rating to a “market perform” rating and cut their price objective for the stock from $5.00 to $4.00 in a research report on Friday, November 15th. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $6.75.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.